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PEMETREXED IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A 
PHASE-I DOSE FINDING STUDY 
ALEXANDRA ELIZABETH MALESZ 
ABSTRACT 
OBJECTIVE: The aim of this study was to investigate the safety and tolerability of a 
novel anti-folate drug, pemetrexed, in the setting of a phase I clinical trial in patients with 
non-HIV related central nervous system lymphoma (CNSL). 
METHODS: In this multicenter, open-label, phase I dose finding clinical trial, 
pemetrexed was investigated as a single agent treatment for primary or secondary CNSL.  
RESULTS: A total of 18 patients were enrolled between January 2009 and November 
2014. The mean age was 64.6 years old (range: 47-79). The ratio of male to female was 
1:1. One out of six patients experienced a dose limiting toxicity (DLT) at dose level 1 
(600mg/m2). There were no DLTs among the four patients enrolled at dose level 2 
(900m/m2). Two of six patients experienced a DLT at dose level 3 (1200mg/m2). The 
MTD was therefore determined to be 900mg/m2. Overall, pemetrexed was well tolerated 
but toxicities were seen and need to be monitored. All patients experienced at least one 
type of toxicity of any grade. Most patients (92.9%) experienced at least one type of 
neurological toxicity. Grade-3 toxicities included confusion, speech impairment, and 
psychosis. Twelve patients (85.7%) experienced at least one bone marrow type of toxicity 
of any grade. These toxicities included anemia (78.6%), thrombocytopenia (57.1%), 
neutropenia (50%), leukocytopenia (42.9%), and lymphopenia (42.9%). Four patients 
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experienced either grade-3 (14.3%) or grade-4 (14.3%) neutropenia. Three patients 
experienced grade-3 leukopenia (21.4%). One patient experienced grade-3 lymphopenia 
(7.1%) and two patients experienced grade-4 lymphopenia (14.3%). Twelve patients 
(85.7%) experienced at least one metabolic type of toxicity of any grade. A majority of 
these were also grade-1 or 2, with the exception of hypophosphatemia (grade-4), 
hyperglycemia (grade-3) and increased ALT (grade-3), increased AST (grade-3) and 
increased creatinine phosphokinase (CPK) (grade-4). Constitutional and gastrointestinal 
symptoms were seen in >60% of patients. These consisted mainly of fatigue, 
constipation, nausea, and anorexia. Musculoskeletal symptoms were seen in greater than 
60% of patients. Less common adverse events included pain (<60%), infection (<40%), 
dermatologic, ocular/visual, and pulmonary/upper respiratory (<30%). The average 
number of cycles on treatment for all patients was 5.5 cycles. 14 patients were evaluated 
for response to treatment by neuroimaging (MRI) while on treatment. Of these, four 
patients (28.6%) showed a complete response (CR). Of those patients, 2 patients achieved 
this response after only 2 doses, and 2 patients after a total of 8 doses. 5 patients (35.7%) 
showed a partial response (PR) and four patients (28.6%) achieved stable disease (SD). 
The overall response rate (ORR) was determined at 92.9% (SD, PR and CR combined). 
CONCLUSIONS: Given this data, pemetrexed is a powerful drug and feasible 
alternative to existing treatment options; however, certain toxicities need to be closely 
monitored. Further studies are needed to assess the efficacy of pemetrexed in a larger 
cohort of patients with CNSL.   
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INTRODUCTION  
Overview 
Non-Hodgkin lymphoma (NHL) refers to a group of malignant neoplasms that 
originate from B or T cell progenitors, mature B or T lymphocytes, or natural killer cells 
(Freedman, Friedberg, & Aster, 2015). Central nervous system lymphoma (CNSL) is a 
subset of NHL that involves the nervous system at any level and can develop within the 
nervous system (primary) or spread into the nervous system (secondary) (Norden, 
Hochberg, & Hochberg, 2016).   
Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal 
NHL that originates in the brain, leptomeninges, spinal cord, or eyes and is usually 
confined to the central nervous system (CNS) and not found anywhere else in the body 
(T. Batchelor & Loeffler, 2006; Ramachandran, 2016). Clinical features and prognosis 
vary depending on the immunocompetence of the patient (T. Batchelor & Loeffler, 
2015). PCNSL incidence increased between the 1960s and 1990s, peaked, and then 
decreased (T. Batchelor & Loeffler, 2015). These trends mainly represented young and 
middle-aged men and reflect changes in human immunodeficiency virus and acquired 
immunodeficiency syndrome (HIV)/(AIDS) rates and introduction of therapies (T. 
Batchelor & Loeffler, 2015; Hoffman, Propp, & McCarthy, 2006; Howlader, Shiels, 
Mariotto, & Engels, 2016; O’Neill, Decker, Tieu, & Cerhan, 2013). The incidence of 
PCNSL in adults over 65 years of age, on the other hand, has continued to increase 
(O’Neill et al., 2013). PCNSL accounts for 4% of all newly diagnosed primary CNS 
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tumors and 1% of all NHL cases, with an incidence rate of 4 cases per million persons 
per year (T. Batchelor & Loeffler, 2015; Villano, Koshy, Shaikh, Dolecek, & McCarthy, 
2011). In contrast, PCNSL is found in 6-20% of HIV positive patients and accounts for 
15% of NHLs in HIV infected patients (Ramachandran, 2016; Coté et al., 1997). Most 
cases of PCNSL occur in patients aged 45 to 65 years, with a median age of 55, whereas 
the median age of HIV-infected patients with PCNSL is 30 years (T. Batchelor & 
Loeffler, 2015; Fine & Mayer, 1993; Ramachandran, 2016). Males are more affected than 
females in both groups (T. Batchelor & Loeffler, 2006). Different prognostic scales for 
PCNSL have been developed, which identify significant risk factors. Older age, lower 
performance status, elevated lactate dehydrogenase (LDH) serum level, elevated CSF 
protein concentration, and involvement of deep brain areas were shown to be indicative 
of a poorer prognosis (Abrey et al., 2006; Andrés J. M. Ferreri et al., 2003). 
 Approximately 90% of PCNSLs are classified as diffuse large B-cell lymphoma 
(DLBCL) while the remaining 10% are low-grade lymphomas, Burkitt’s lymphomas, and 
T-cell lymphomas (T. Batchelor & Loeffler, 2006). DLBCL presents with immunoblast 
or centroblast lymphoid aggregates around small cerebral vessels. The tumor cells are 
usually pleomorphic with large nuclei and a coarse chromatin pattern (T. Batchelor & 
Loeffler, 2006). PCNSL is thought to be a “late germinal center or post-germinal center 
lymphoid neoplasm” and there is uncertainty about whether the malignant transformation 
occurs within normally trafficking CNS lymphocytes or systemically in lymphocytes 
with tropism for the CNS (T. Batchelor & Loeffler, 2006, 2015). Different cell-surface 
molecules and chemokine receptors are thought to play a role (T. Batchelor & Loeffler, 
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2015). More research still needs to be done but the increased occurrence of PCNSL in 
immunocompromised individuals suggests the importance of the immune system in the 
pathogenesis (T. Batchelor & Loeffler, 2015). 
Despite the fact that malignancies originate from lymphocytes, PCNSL is 
classified as a brain tumor (Ramachandran, 2016). Similar to other brain tumors, neural 
toxicities and the blood brain barrier impair efficient drug delivery, making treatment for 
PCNSL difficult (Ramachandran, 2016). 
Clinical signs of PCNSL vary depending on areas of involvement, but most 
frequently present as symptoms related to periventricular lesions in the brain including 
focal neurological deficits, neuropsychiatric symptoms, signs of increased intracranial 
pressure, seizure, and/or ocular symptoms (Bataille et al., 2000; T. Batchelor & Loeffler, 
2015). Approximately 40% of patients with cerebral PCNSL may have leptomeningeal 
involvement, which presents with cranial neuropathies, spinal symptoms, headache, focal 
weakness, ataxia, and encephalopathy (T. Batchelor & Loeffler, 2015; Taylor et al., 
2013). About 15 to 25% of patients with PCNSL have some involvement of the eye (T. 
Batchelor & Loeffler, 2015). PCNSL that initially presents in the eye is referred to as 
primary intraocular lymphoma (PIOL) and includes non-specific ocular and visual 
symptoms (T. Batchelor & Loeffler, 2015). Primary spinal involvement occurs in less 
than 1% of patients with PCNSL and usually presents as a progressive myelopathy. 
Finally, neurolymphomatosis (NL) refers to the lymphomatous invasion of nerve roots of 
the cranial or spinal nerves, which may present with sensory and/or motor dysfunctions 
and neuropathy (T. Batchelor & Loeffler, 2015; Grisariu et al., 2010).  
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Secondary central nervous system lymphoma (SCNSL) involves the spread of 
systemic NHL to the nervous system (Norden et al., 2016). The pathogenesis, 
epidemiology, and presentation of SCNSL are different from PCNSL and will not be 
discussed here. However, similar to PCNSL, there is no standard treatment for SCNSL. 
Diagnosis 
 Patients suspected of having PCNSL should have a history and physical 
examination done, as well as imaging of the CNS, preferably with contrast-enhanced 
magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, slit lamp 
examination of both eyes, and testicular examination and ultrasound in males (T. 
Batchelor & Loeffler, 2015). Diagnosis includes histopathological evaluation of tissue, 
usually done by stereotactic brain biopsy (Hoang-Xuan et al., 2015). Corticosteroids 
should be avoided prior to imaging or biopsy, as these agents are lymphocytotoxic and 
may cause any tumor to temporarily disappear (T. Batchelor & Loeffler, 2015). 
Diagnosis may be made by pathological evaluation of vitreal biopsies (in the case of 
ocular lymphoma) or CSF analysis (T. Batchelor & Loeffler, 2015).  
 Once PCNSL is diagnosed, additional steps should be taken to assess the extent of 
disease and to guide treatment (Abrey et al., 2005). This includes laboratory studies, HIV 
testing, full ophthalmological evaluation, bone marrow biopsy, contrast-enhanced 
computed tomography (CT) of the chest, abdomen, and pelvis to confirm absence of 
systemic disease, performance status using the Karnofsky performance scale (KPS) or 
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Eastern Cooperative Oncology Group (ECOG) scale, and cognitive function evaluations 
(T. Batchelor, 2015). 
Treatment 
 Currently, treatment for PCNS lymphoma varies and recommendations are 
evolving (T. Batchelor, 2015). For immunocompetent patients with newly diagnosed 
PCNSL, treatment includes corticosteroids and chemotherapy (Hoang-Xuan et al., 2015). 
PCNSL tends to be a diffuse disease, rather than localized, and therefore surgery is not 
recommended. A biopsy is usually performed for diagnostic purposes only since 
resection of tumor has not been shown to provide any benefit (T. Batchelor & Loeffler, 
2015; Hoang-Xuan et al., 2015). While whole-brain radiation therapy (WBRT) was 
historically used to target the multifocal features of PCNSL, use of WBRT in initial 
treatment has decreased due to the fact that it is neurotoxic and has not shown a 
significant overall survival benefit (A. J.M. Ferreri et al., 2002; Korfel et al., 2015). It is 
currently used as part of salvage therapy in patients who have not responded to other 
therapies or those who are not candidates for chemotherapy (T. Batchelor, 2015). 
 Methotrexate (MTX) is a folate antagonist that disrupts DNA biosynthesis and is 
the most used drug for PCNSL (T. Batchelor & Loeffler, 2006). MTX must be given 
intravenously at high doses in order to penetrate into the CNS; doses range from 3.5 to 8 
g/m2 (T. Batchelor, 2015). This high-dose methotrexate (HD-MTX) chemotherapy is 
given during the “induction” stage and is the standard initial therapy for PCNSL (T. 
Batchelor & Loeffler, 2006). MTX can be given alone or in combination with other 
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drugs, such as cytarabine, temozolomide, procarbzaine, vincristine, and rituximab (T. 
Batchelor, 2015). 
 Once a response is seen from induction therapy, the “consolidation” stage 
follows. There is no standard consolidation therapy but current regiments include 
continued MTX, second-line chemotherapies, high-dose chemotherapy with autologous 
hematopoietic cell transplant, WBRT, or supportive care (Hoang-Xuan et al., 2015). 
Despite their initial response, almost all patients with PCNSL will relapse or have tumor 
progression and will require salvage therapies (T. Batchelor & Loeffler, 2006). 
Despite numerous studies done to compare different therapies and combination 
therapies (T. T. Batchelor, 2013; Chen et al., 2015; A. J.M. Ferreri et al., 2002; Korfel et 
al., 2015; Pollack, Lunsford, Flickinger, & Dameshek, 1989; Ponzoni, Issa, Batchelor, & 
Rubenstein, 2014; Soussain et al., 2001), there is still no known optimal regimen for 
PCNSL. HD-MTX remains the best treatment as of date. However, a major drawback of 
MTX chemotherapy is that it requires inpatient hospitalization for at least three days to 
monitor drug clearance and renal clearance. It also has numerous toxic side effects and 
may ultimately confer resistance (LaCasce, 2016). 
Pemetrexed 
Pemetrexed disodium heptahydrate has the chemical name L-Glutamic acid, N-[4- 
[2-(2amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d] pyrimidin-5-yl)ethyl]benzoyl]-, 
disodium salt, heptahydrate. The brand name is Alimta. Figure 1 shows its structural 
formula.  
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Figure 1. Structure of Pemetrexed (Muhsin, Gricks, & Kirkpatrick, 2004) 
 
 Pemetrexed is a synthetic pyrimidine-based anti-folate that disrupts folate 
dependent metabolic processes essential for DNA synthesis and cell replication (Muhsin 
et al., 2004). Studies have shown that it inhibits thymidylate synthase (TS), dihydrofolate 
reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all 
folate-dependent enzymes involved in the de novo synthesis of thymidine and purine 
nucleotides (Chattopadhyay, Moran, & Goldman, 2007; Shimizu et al., 2012). 
Pemetrexed is transported into cells by membrane carriers and once inside the cell, is 
converted to polyglutamate forms, which inhibit TS and GARFT (Baugh, Krumdieck, & 
Nair, 1973; Whitehead, 1977). This polyglutamation is a process that occurs 
predominantly in tumor cells and produces metabolites that have an increased 
intracellular half life, therefore prolonging drug action in malignant cells (Fry, Yalowich, 
& Goldman, 1982; Jolivet & Chabner, 1983; Jolivet, Schilsky, Bailey, Drake, & Chabner, 
1982; Rosenblatt, Whitehead, Dupont, Vuchich, & Vera, 1978). 
 Pemetrexed has a similar structure and function to MTX. As with MTX, 
pemetrexed needs to be administered with supplementation to prevent drug related 
toxicities. However, benefits of pemetrexed include higher uptake and increased 
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intracellular half life, no hospitalization required, and added efficacy in MTX failure or 
MTX resistance (Dai, Chen, & Elmquist, 2005). 
Use in Other Cancers 
 Pemetrexed has been approved by the U.S. Food and Drug Administration (FDA) 
for maintenance treatment of patients with non-squamous non-small cell lung cancer, 
initial treatment of non-squamous non-small cell lung cancer in combination with 
cisplatin therapy, and malignant pleural mesothelioma in combination with cisplatin 
therapy (Cohen, Cortazar, Justice, & Pazdur, 2010). 
 The most common toxicities found in phase III studies included fatigue, nausea, 
and anorexia (found in more than 20% of patients) (Paz-Ares et al., 2012). Hematological 
toxicities (anemia, leukopenia, neutropenia, and thrombocytopenia) were seen in patients, 
however, these were significantly reduced when patients were supplemented with folic 
acid and vitamin B12 (Vogelzang et al., 2003). 
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AIM AND OBJECTIVES 
 Pemetrexed is an FDA approved drug that is a potential treatment for CNS 
lymphoma. The aim of this study was to investigate the safety and tolerability of 
pemetrexed in the setting of a phase I clinical trial in patients with non-AIDS related 
PCNS lymphoma. Proper  
The objectives were: 
- To determine the maximum tolerated dose (MTD) of pemetrexed. 
- To assess all toxicities experienced by patients enrolled in the clinical trial at all 
all study sites. 
- To determine the most common adverse events related to pemetrexed. 
- To evaluate the overall response rate (ORR). 
- To provide recommendations for future studies. 
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METHODS 
Trial Design (“Treatment of Recurrent Primary or Secondary Central Nervous System 
(CNS) Lymphoma With ALIMTA (Pemetrexed),” 2015) 
 The study was designed as a multicenter, open-label, phase I dose finding clinical 
trial to analyze the safety and tolerability of pemetrexed in the treatment of recurrent 
primary or secondary CNS lymphoma. Patients with newly diagnosed PCNSL were also 
able to enroll if they were otherwise unable to be treated with a high-dose Methotrexate-
based regimen, the current standard of care. 
The primary objective was to determine the maximum tolerated dose (MTD) of 
pemetrexed as a single agent. Secondary objectives were to determine the plasma 
pharmacokinetics of pemetrexed and assessment of drug penetration into the 
cerebrospinal fluid (CSF), to provide preliminary evidence of pemetrexed activity against 
lymphoma by MRI criteria using tumor volume reduction including MR diffusion, 
perfusion, and blood flow, or clearance of CSF lymphoma cells, and to provide the basis 
for a phase II trial. Quality of life was also assessed. Eli Lilly, Inc., provided the 
investigational drug.  
Recruitment 
 The study was conducted at three different locations within the Dana Farber/ 
Harvard Cancer Center (DFHCC), including the Massachusetts General Hospital (MGH), 
the Dana Farber Cancer Institute (DFCI), and Beth Israel Deaconess Medical Center. 
Subjects were eligible to participate if they met all inclusion criteria. Patients had to be 18 
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years or older with pathologically confirmed high grade Non Hodgkin lymphoma 
involving the nervous system, which includes parenchymal brain tumor, ocular-vitreous 
or retinal lymphoma with measureable brain involvement; nerve seeking lymphoma as 
neurolymphomatosis and lymphamatous involvement of the spinal fluid or meninges 
(lymphomatous meningitis) (“Treatment of Recurrent Primary or Secondary Central 
Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed),” 2015). Patients were 
allowed to have prior or concurrent systemic lymphoma as long as the nervous system 
had measureable disease per MRI imaging (“Treatment of Recurrent Primary or 
Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed),” 
2015). Significant exclusion criteria included prior whole brain radiation, 
immunosuppression, and patients with decreased creatinine clearance, increased serum 
creatinine, or increased liver function tests (“Treatment of Recurrent Primary or 
Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed),” 
2015). Full eligibility criteria details can be found in Appendices I and II. Patients had to 
provide written consent and were registered with the central Quality Assurance for 
Clinical Trials (QACT). 
Treatments 
 Pemetrexed was given as a 10-20 minute intravenous (IV) infusion every two 
weeks. This was supplemented with folic acid daily and vitamin B12 starting 7 days 
before pemetrexed administration, and Neupogen for bone marrow support on days 4, 5, 
and 6 after pemetrexed administration. Each two-week period was considered one cycle. 
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Subjects were evaluated by MRI every two cycles (monthly) until a complete response 
(CR) was achieved or until their eighth cycle. Patients who had progressive disease (PD) 
after at least four cycles of pemetrexed or stable disease at cycle eight were removed 
from the study. Patients who achieved a CR by MRI received two additional 
consolidative cycles of pemetrexed and then continued to receive maintenance 
pemetrexed every month to complete 12 months of therapy. Patients who achieved a 
partial response (PR) continued to receive pemetrexed every two weeks until CR, PD or 
stable disease (SD) for eight additional cycles after PR. The full patient study schedule is 
detailed in Appendix III.  
Safety 
All clinical events were monitored and reported throughout the entire study. 
These were documented in case report forms (CRFs) using standard medical terminology. 
Definitions and guidelines for reporting events are outlined below.  
A clinical event was defined as “any untoward event which occurs after exposure 
to the study drug, regardless of causality and whether or not considered to be study drug 
related, including any side effect, illness or injury to the subject, toxicity or sensitivity 
reaction, abnormal change in laboratory value” (“Treatment of Recurrent Primary or 
Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed),” 
2015). An adverse event (AE) was defined as “a clinical event, which is clinically 
significant. An AE may include changes in signs, symptoms, pre-existing conditions, or 
laboratory tests. Clinical events, which lead to the addition of concomitant medication or 
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an increase in the dose or frequency of concomitant medication, are generally considered 
clinically significant. An abnormal test result is considered an AE if: (1) it is not 
associated with an already reported AE or diagnosis, or pre-existing condition, and there 
is an impact on test article administration, or there is a change in concomitant medication, 
or (2) the abnormal test result indicates a serious or life-threatening condition” 
(“Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) 
Lymphoma With ALIMTA (Pemetrexed),” 2015). A serious adverse event (SAE) was 
defined as “any clinical event that is fatal or life-threatening, is permanently disabling, 
requires or prolongs hospitalization, or one that is a congenital anomaly, or drug 
overdose, or is significant for any other reason” (“Treatment of Recurrent Primary or 
Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed),” 
2015).   
The DFHCC Institutional Review Board (IRB) was notified of all AEs within 
reporting guidelines. All serious and unexpected events associated with the use of the 
study medication were reported by MGH to the appropriate regulatory agencies as a 
safety report. Copies of the safety report were provided to all investigators conducting 
clinical trials with the test article. SAEs occurring after a patient was discontinued from 
the study were reported if they occurred within 30 days of coming off study. SAEs that 
were assessed as being due to disease progression and not due to study drug were 
excluded from AE reporting. The full standard operating procedure for reporting events 
can be found in Appendix IV. 
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Three patients per dose level cohort were treated and evaluated for toxicity over a 
period of 28 days (two cycles of pemetrexed). This time frame was chosen because 
previous studies have shown that toxicities most often occur within 14 days of treatment 
(Hanna et al., 2004; Melemed et al., 2005; Vogelzang et al., 2003). 
Toxicities were evaluated based on the manual of common terminology for 
adverse events (CTCAE), version 3. The grade refers to the severity of the AE. Grade 1 
corresponds to a mild AE, grade 2 to a moderate AE, grade 3 to a severe AE, grade 4 to a 
life-threating or disabling AE, and grade 5 to a death related AE. Table 1 shows two 
examples of the grading scale from the CTCAE manual. 
 
Table 1. Grading (Severity) Scale For Adverse Event Reporting 
Adapted from CTCAEv3.0 manual (DCTD, NCI, NIH, & DHHS, 2006) 
TOXICITY GRADE 1 GRADE 2 GRADE 3 GRADE 4 GRADE 5 
Hemoglobin <LLN - 10.0 
g/dL 
< 10.0 - 8.0 
g/dL 
< 8.0 - 6.5 
g/dL 
< 6.5 g/dL Death 
Fatigue Mild fatigue 
over 
baseline 
Moderate or 
causing 
difficulty 
performing 
some ADL 
Severe fatigue 
interfering 
with ADL 
Disabling Death 
 
Escalation to the next dose level cohort proceeded when no dose limiting toxicity 
(DLT) was observed. When a drug-related DLT occurred at any dose level cohort, three 
additional patients were added to this dose level cohort. Similarly, a serious adverse event 
(SAE) attributable to the investigational agent would also expand the dose level by three 
additional patients. The MTD was determined to be the dose level cohort below the DLT.  
15 
A DLT was defined as any event of grade-4 toxicity (with the exceptions listed 
below in Table 2) and any grade-3 non-hematologic, non-neurologic toxicity (with the 
exception below) that occurred within the first two cycles (28 days) of therapy or the 14-
day observation period between each dose level cohort. Grade-4 neurologic adverse 
events were only considered a DLT if the investigator had deemed it at least probably 
related to pemetrexed. 
Table 2. Dose Limiting Toxicity Guidelines 
 DLT Not Considered a DLT 
Hematologic Grade-4 Grade-4 neutropenia that 
lasts <5 days and is not 
associated with fever or 
infection (may receive 
Neupogen or Granix) 
Non-hematologic Grade-3 Nausea, Vomiting, 
Diarrhea unresponsive to optimal 
supportive therapy 
 
Liver function Grade-3 and definitely associated 
with pemetrexed 
 
Neurologic 25% increase in seizure 
frequency, or change in seizure 
description, 
worsened focal weakness, 
evidence of clinical brain 
herniation,  
Increase in corticosteroids by 
50%, 
clinical or brain MRI evidence of 
brain hemorrhage or infection 
Cerebral swelling (25% 
increase in FLAIR 
abnormality on MRI) 
 
 If toxicities did not return to baseline or grade-1, treatment was delayed by 1-
week increments. If therapy was delayed by more than three weeks, or if more than two 
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dose reductions were required, the patient would be ineligible for further therapy. Dose 
reduction guidelines are outlined in Table 3. 
 
Table 3. Dose Reduction Guidelines 
Toxicity Dose Reduction 
- ANC < 1,000/mm3 for 5+ days 
- ANC < 500/mm3 
- Platelets < 50,000/mm3 for 7+ days, or when 
associated with grade 3+ bleeding requiring platelet 
transfusion 
25% dose reduction 
Persistent Grade-3 hepatic toxicity (does not return to 
grade 1 prior to next cycle) 
25% dose reduction 
Grade-3 stomatitis/mucositis 50% dose reduction 
Creatinine clearance <45mL/min,  Reduced based on 
percentage decrease 
under 100mL/min 
Grade-3 or 4 non-hematologic toxicities 25% dose reduction 
  
Pharmacokinetic Studies 
 The pharmacokinetic (PK) study was performed in all subjects in the trial on 
weeks 1 and 3. A large gauge peripheral catheter was placed opposite to the arm used for 
infusion of the drug. Venous blood samples were collected prior to infusion, at 0, 5 and 9 
minutes during infusion, at end of infusion, and 5 and 20 minutes, 1, 2, 4, 6, 24, 48, and 
72 hours from the start of infusion. Blood samples were collected in 6.0mL Vacutainer 
collection tubes with spray-coated sodium heparin. The plasma fraction was separated, 
and kept at   -70oC until assayed. 
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RESULTS 
A total of 18 patients were enrolled into this study across all three sites between 
January 2009 and November 2014. The mean age was 64.6 years old (range:47-79 
median:66.5). The ratio of male to female was 1:1. Patients had a diagnosis of primary or 
secondary non-Hodgkin lymphoma of the CNS. Two patients with an initial diagnosis of 
PCNSL were unable to be treated with methotrexate. The mean KPS for all patients at 
baseline was 82.4%. 
Table 4. Patient Demographics 
Characteristic   
Mean age (range) 64.6 (47-79) 
Male:Female 9:9 
Mean KPS (%) 82.4 
Race  
White 14 
Black 1 
Asian 1 
Other 2 
Disease State  
PCNSL 2 
Recurrent PCNSL 14 
Recurrent SCNSL 2 
 
 
Three patients were started at dose level 1 (=600mg/m2) and received two cycles 
of pemetrexed. One patient (subject 1) in that dose level cohort experienced grade-4 
neutropenia, which was considered a DLT. As per protocol, three additional patients were 
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enrolled into dose level 1 at 600mg/m2. Due to the absolute neutrophil count (ANC) 
toxicity, the protocol was amended to state that all patients would be treated with 
Neupogen or Granix for bone marrow support. One subject (subject 5) withdrew consent 
before treatment began so that patient slot was replaced. No additional DLTs were 
observed, so cohort 2 was opened at 900 mg/m2 and enrolled three patients. None of the 
patients at dose level 2 experienced a DLT and cohort 3 was opened at 1200 mg/m2. One 
subject (subject 11) experienced a DLT of grade-4 lymphopenia and three additional 
patients were enrolled into cohort 3. One of these additional patients also experienced 
grade-4 lymphopenia. Since two out of six patients experienced DLTs at this dose level, 
the MTD was determined to be dose level 2, or 900mg/m2. The next patient (subject 17) 
was enrolled back into dose level 2. However, an interim analysis was performed and it 
was determined that one subject (15) who experienced a DLT in cohort 3, was unable to 
be evaluated. Therefore, one more patient (subject 18) was enrolled at 1200mg/m2 to 
replace that subject. After another subject (subject 16) in cohort 3 also experienced a 
DLT, the MTD was confirmed to be 900mg/m2 (dose level 2).  
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Table 5. Summary of Dose Limiting Toxicities  
 
 
Pemetrexed, 
mg/m2 No. of Patients 
No. Who Did Not 
Receive Cycle 2 No. of patient with DLT 
600 (Dose level 1) 6 0 1 (grade 4 lymphopenia after C2) 
900 (Dose level 2) 4 1 0 
1200 (Dose level 3) 7 2 2 (grade 4 lymphopenia after C1; grade 3 fatigue) 
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Fourteen out of eighteen patients were evaluated for toxicities, or AEs, while on 
treatment, while 4/18 patients did not reach the time point for toxicity assessment so they 
were not included in the evaluation. However, any SAEs experienced by those patients 
are reviewed in the next section.  
Toxicities were categorized into 17 different categories based on different organs 
or systems. Table 6 shows the number and percent of subjects who experienced an 
adverse event and which grade. All 14 patients experienced at least one toxicity (100%).  
The most common toxicities seen were neurological events. Thirteen patients 
(92.9%) experienced at least 1 neurological symptom of any grade. Of these symptoms, 
the most common were anxiety (42.9%), depression (28.6%), confusion, sensory 
neuropathy (21.4%), seizure (21.4%), and speech impairment (21.4%). Most of these 
neurological toxicities were either grade-1 or 2. The only exceptions were grade-3 
toxicities including confusion (14.3%), speech impairment (7.1%), and psychosis (7.1%). 
There were no grade-4 or 5 neurological adverse events.  
The other most frequently seen adverse events were hematological and 
metabolic/laboratory toxicities. Twelve patients (85.7%) experienced at least one bone 
marrow toxicity of any grade. The most common event was anemia, or decreased 
hemoglobin (78.6%). Two of the patients experienced grade-3 anemia (14.3%), while the 
other patients experienced either grade-1 (35.7%) or grade-2 (28.6%). Other common 
events included decreased platelet count (thrombocytopenia) (57.1%), decreased ANC 
(neutropenia) (50%), decreased white blood cells (WBCs)/leukocytes (42.9%), and 
decreased lymphocytes (lymphopenia) (42.9%). Four patients experienced either grade-3 
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(14.3%) or grade-4 (14.3%) neutropenia. Three patients experienced grade-3 
leukocytopenia (21.4%). One patient experienced grade-3 lymphopenia (7.1%) and two 
patients experienced grade-4 lymphopenia (14.3%). Twelve patients (85.7%) experienced 
at least one metabolic toxicity of any grade. The most common event was 
hypophosphatemia, or low serum phosphorus (71.4%). Of these, 1 patient had a grade-3 
toxicity, and 1 patient had a grade-4 toxicity. Other common toxicities were increased 
alanine transaminase (ALT) (64.3%), increased aspartate aminotransferase (AST) (50%), 
and hyperglycemia (42.9%). Two patients (14.3%) experienced a grade-3 ALT event, 1 
patient (7.1%) experienced a grade-3 AST event, and 1 patient (7.1%) experienced grade-
3 hyperglycemia. Additionally, 1 patient (7.1%) experienced a grade-3 serum creatinine 
phosphokinase (CPK) toxicity. See Table 6 for all metabolic toxicities. 
Eleven patients (78.6%) experienced at least 1 constitutional symptom of any 
grade. The most notable toxicity in this category was fatigue (71.4%), with one patient 
experiencing a grade-3 event. Nine patients (64.3%) had at least one musculoskeletal 
toxicity. Nine patients (64.3%) experienced at least one gastrointestinal adverse event. 
Eight patients (57.1%) had at least one pain event. Five patients (35.7%) experienced an 
infection. Of these, 1 patient experienced grade-4 febrile neutropenia (7.1%), 1 patient 
experienced a grade-3 joint infection with a concurrent ANC that was grade 0-2 (7.1%), 
and 1 patient experienced a catheter related infection with an unknown ANC (7.1%). 
Four patients (28.6%) experienced at least 1 event in the following categories: 
dermatology, ocular/visual, and pulmonary/upper respiratory. These were all grade-1 or 
grade-2 events. Three patients experienced at least one renal/genitourinary toxicity 
22 
(21.4%) and a cardiac toxicity (21.4%). One patient (7.1%) experienced a toxicity in the 
following categories: allergic rhinitis, endocrine, bleeding, and lymphatics. These were 
either grade-1 or grade-2. See Table 6 for additional details. 
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Table 6. Toxicities Across All Cycles of Therapy 
TOXICITY (n=14) 
GRADE 
1 
GRADE 
2 
GRADE 
3 
GRADE 
4 
ALL 
GRADES 
ALLERGY/IMMUNOLOGY         1 (7.1%) 
Allergic rhinitis 0 1 (7.1%) 0 0 1 (7.1%) 
BLOOD/BONE MARROW         12 (85.7%) 
Hemoglobin 5 (35.7%) 4 (28.6%) 2 (14.3%) 0 11 (78.6%) 
Platelets 7 (50.0%) 1 (7.1%) 0 0 8 (57.1%) 
Neutrophils 1 (7.1%) 2 (14.3%) 2 (14.3%) 2 (14.3%) 7 (50.0%) 
Leukocytes 2 (14.3%) 1 (7.1%) 3 (21.4%) 0 6 (42.9%) 
Lymphopenia 0 3 (21.4%) 1 (7.1%) 2 (14.3%) 6 (42.9%) 
Bone marrow cellularity 0 1 (7.1%) 0 0 1 (7.1%) 
Hematologic, other 0 1 (7.1%) 0 0 1 (7.1%) 
CARDIAC         3 (21.4%) 
Hypotension 2 (14.3%) 0 0 0 2 (14.3%) 
Hypertension 1 (7.1%) 0 0 0 1 (7.1%) 
CONSTITUTIONAL SYMPTOMS       11 (78.6%) 
Fatigue 4 (28.6%) 5 (35.7%) 1 (7.1%) 0 10 (71.4%) 
Constitutional, other 3 (21.4%) 0 0 0 3 (21.4%) 
Insomnia 3 (21.4%) 0 0 0 3 (21.4%) 
Sweating 2 (14.3%) 1 (7.1%) 0 0 3 (21.4%) 
Fever w/o neutropenia 2 (14.3%) 0 0 0 2 (14.3%) 
Weight loss 1 (7.1%) 0 0 0 1 (7.1%) 
DERMATOLOGY/SKIN         4 (28.6%) 
Rash: acne/acneiform 1 (7.1%) 1 (7.1%) 0 0 2 (14.3%) 
Bruising 1 (7.1%) 0 0 0 1 (7.1%) 
Flushing 0 1 (7.1%) 0 0 1 (7.1%) 
Skin breakdown/decubitus ulcer 0 1 (7.1%) 0 0 1 (7.1%) 
Skin, other 1 (7.1%) 0 0 0 1 (7.1%) 
ENDOCRINE         1 (7.1%) 
Cushingnoid appearance 0 1 (7.1%) 0 0 1 (7.1%) 
GASTROINTESTINAL         9 (64.3%) 
Constipation 4 (28.6%) 0 0 0 4 (28.6%) 
Nausea 3 (21.4%) 1 (7.1%) 0 0 4 (28.6%) 
Anorexia 2 (14.3%) 1 (7.1%) 0 0 3 (21.4%) 
Dyspepsia 1 (7.1%) 1 (7.1%) 0 0 2 (14.3%) 
Vomiting 1 (7.1%) 1 (7.1%) 0 0 2 (14.3%) 
Diarrhea w/o prior colostomy 1 (7.1%) 0 0 0 1 (7.1%) 
Muco/stomatitis (symptom) 1 (7.1%) 0 0 0 1 (7.1%) 
Taste Disturbance 0 1 (7.1%) 0 0 1 (7.1%) 
HEMORRHAGE/BLEEDING         1 (7.1%) 
Nose, hemorrhage 1 (7.1%) 0 0 0 1 (7.1%) 
INFECTION         5 (35.7%) 
Infection Gr0-2 neut, urinary tract 0 2 (14.3%) 0 0 2 (14.3%) 
Febrile neutropenia 0 0 0 1 (7.1%) 1 (7.1%) 
Infection Gr0-2 neut, joint 0 0 1 (7.1%) 0 1 (7.1%) 
Infection w/ unk ANC catheter 
related 0 0 1 (7.1%) 0 1 (7.1%) 
Infection w/ unk ANC skin 
(cellulitis) 1 (7.1%) 0 0 0 1 (7.1%) 
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LYMPHATICS         1 (7.1%) 
Edema limb 0 1 (7.1%) 0 0 1 (7.1%) 
METABOLIC/LABORATORY         12 (85.7%) 
Hypophosphatemia 1 (7.1%) 7 (50.0%) 1 (7.1%) 1 (7.1%) 10 (71.4%) 
ALT/SGPT 6 (42.9%) 1 (7.1%) 2 (14.3%) 0 9 (64.3%) 
AST/SGOT 5 (35.7%) 1 (7.1%) 1 (7.1%) 0 7 (50.0%) 
Hyperglycemia 2 (14.3%) 3 (21.4%) 1 (7.1%) 0 6 (42.9%) 
Creatinine 2 (14.3%) 2 (14.3%) 0 0 4 (28.6%) 
Bicarbonate 3 (21.4%) 0 0 0 3 (21.4%) 
Hypermagnesemia 3 (21.4%) 0 0 0 3 (21.4%) 
Hypokalemia 2 (14.3%) 1 (7.1%) 0 0 3 (21.4%) 
Hyponatremia 3 (21.4%) 0 0 0 3 (21.4%) 
Proteinuria 3 (21.4%) 0 0 0 3 (21.4%) 
Alkaline phosphatase 2 (14.3%) 0 0 0 2 (14.3%) 
Hypoalbuminemia 2 (14.3%) 0 0 0 2 (14.3%) 
Metabolic/Laboratory-other 2 (14.3%) 0 0 0 2 (14.3%) 
Amylase 1 (7.1%) 0 0 0 1 (7.1%) 
Bilirubin 0 1 (7.1%) 0 0 1 (7.1%) 
CPK 0 0 1 (7.1%) 0 1 (7.1%) 
Hypercalcemia 0 1 (7.1%) 0 0 1 (7.1%) 
Hypercholesterolemia 1 (7.1%) 0 0 0 1 (7.1%) 
Hyperkalemia 1 (7.1%) 0 0 0 1 (7.1%) 
Hyperuricemia 1 (7.1%) 0 0 0 1 (7.1%) 
Hypocalcemia 1 (7.1%) 0 0 0 1 (7.1%) 
Hypoglycemia 1 (7.1%) 0 0 0 1 (7.1%) 
Hypomagnesemia 1 (7.1%) 0 0 0 1 (7.1%) 
MUSCULOSKELETAL         9 (64.3%) 
Nonneuropathic gen weak 3 (21.4%) 3 (21.4%) 0 0 6 (42.9%) 
Extremity-lower (gait/walking) 0 1 (7.1%) 1 (7.1%) 0 2 (14.3%) 
Fracture 0 0 1 (7.1%) 0 1 (7.1%) 
Musculoskeletal/soft tissue, other 1 (7.1%) 0 0 0 1 (7.1%) 
Nonneuropathic LE muscle weak 0 1 (7.1%) 0 0 1 (7.1%) 
NEUROLOGY         13 (92.9%) 
Anxiety 5 (35.7%) 1 (7.1%) 0 0 6 (42.9%) 
Depression 4 (28.6%) 0 0 0 4 (28.6%) 
Confusion 0 1 (7.1%) 2 (14.3%) 0 3 (21.4%) 
Neuropathy-sensory 2 (14.3%) 1 (7.1%) 0 0 3 (21.4%) 
Seizure 0 3 (21.4%) 0 0 3 (21.4%) 
Speech impairment 0 2 (14.3%) 1 (7.1%) 0 3 (21.4%) 
Ataxia 1 (7.1%) 1 (7.1%) 0 0 2 (14.3%) 
Dizziness 1 (7.1%) 1 (7.1%) 0 0 2 (14.3%) 
Memory impairment 1 (7.1%) 1 (7.1%) 0 0 2 (14.3%) 
Agitation 1 (7.1%) 0 0 0 1 (7.1%) 
Leak, CSF 0 1 (7.1%) 0 0 1 (7.1%) 
Mental status 0 1 (7.1%) 0 0 1 (7.1%) 
Psychosis 0 0 1 (7.1%) 0 1 (7.1%) 
OCULAR/VISUAL         4 (28.6%) 
Tearing 3 (21.4%) 0 0 0 3 (21.4%) 
Ocular, other 2 (14.3%) 0 0 0 2 (14.3%) 
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Vision-blurred 2 (14.3%) 0 0 0 2 (14.3%) 
PAIN         8 (57.1%) 
Head/headache 3 (21.4%) 0 0 0 3 (21.4%) 
Joint, pain 1 (7.1%) 1 (7.1%) 0 0 2 (14.3%) 
Back, pain 1 (7.1%) 0 0 0 1 (7.1%) 
Bone, pain 1 (7.1%) 0 0 0 1 (7.1%) 
Neck, pain 1 (7.1%) 0 0 0 1 (7.1%) 
Pain NOS 1 (7.1%) 0 0 0 1 (7.1%) 
Pain, other 0 1 (7.1%) 0 0 1 (7.1%) 
PULMONARY/UPPER RESPIRATORY       4 (28.6%) 
Dyspnea 2 (14.3%) 0 0 0 2 (14.3%) 
Cough 1 (7.1%) 0 0 0 1 (7.1%) 
Voice changes/dysarthria 0 1 (7.1%) 0 0 1 (7.1%) 
RENAL/GENITOURINARY         3 (21.4%) 
Incontinence urinary 0 1 (7.1%) 0 0 1 (7.1%) 
Urinary frequency/urgency 1 (7.1%) 0 0 0 1 (7.1%) 
Urinary retention 0 1 (7.1%) 0 0 1 (7.1%) 
Urine color 1 (7.1%) 0 0 0 1 (7.1%) 
Renal/GU, other 0 1 (7.1%) 0 0 1 (7.1%) 
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SAEs were reported in 8 patients (47.1%). In some cases, patients experienced 
multiple toxicities at the same time. These are noted in Table 7. Five hematological 
events were considered SAEs. These included grade-3 anemia (5.9%), grade-4 
lymphopenia (11.8%), and grade-4 neutropenia (11.8%). Two SAEs were gastrointestinal 
symptoms: grade-3 dehydration (5.9%) and grade-3 vomiting (5.9%). One patient 
experienced grade-3 infection of a port catheter with a normal ANC (5.9%). There were 
two events of hypophosphatemia (11.8%), one grade-2 event and one grade-4 event. Two 
SAEs consisted of seizures (11.8%): one grade-2 event, and one grade-3 event. Finally, 
there was one grade-2 episode of dyspnea (5.9%).  
Table 7. Serious Adverse Events 
SERIOUS ADVERSE EVENT GRADE 1 GRADE 2 GRADE 3 GRADE 4 
BLOOD/BONE MARROW      
Anemia	   1   
Lymphopeniaª    2 
Neutropenia*    2 
GASTROINTESTINAL      
Dehydrationª   1   
Vomitingª   1   
INFECTION      
Infection, port sepsis, normal ANC   1   
METABOLIC/LABORATORY    		
Hypophosphatemia  1  1 
NEUROLOGY    		
Seizure*ª  1ª 1*   
PULMONARY/RESPIRATORY    		
Dyspnea	   1     
*One combined SAE experienced by patient 1     
ªOne combined SAE experienced by patient 11     
	One combined SAE experienced by patient 14       
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The average number of cycles on treatment for 17 patients was 5.5 cycles (SD 
3.7). 14 patients were evaluated for response by MRI while on treatment. Four patients 
did not reach the time point for first imaging after 4 weeks (2 cycles of treatment) so 
response could not be evaluated. Figure 2 shows the best response and time on study for 
patients who were evaluable (n=14). Four patients (28.6%) showed a CR. Of those 
patients, 2 patients achieved this response after only 2 doses, and 2 patients after 8 doses. 
5 patients (35.7%) showed a PR. Four patients achieved SD. The overall response rate 
(ORR) was 92.9% (SD, PR and CR combined).  
 
Figure 2. Best Response and Time on Therapy 
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DISCUSSION 
 Despite the fact that the history of CNSL has been well documented and there has 
been much research done, the disease remains poorly understood. Currently, there is no 
standard treatment regimen for either newly diagnosed or recurrent disease. The best 
available option for treatment consists of a HD-MTX based regimen. HD-MTX requires 
inpatient hospitalization for at least a couple of days. Even though MTX produces a 
beneficial response in a majority of patients, almost all patients will have relapse or 
progression at some point and will require salvage therapy (T. Batchelor & Loeffler, 
2006). Pemetrexed is a novel drug that has similar actions to MTX but may offer added 
efficacy and does not require inpatient hospitalization. Pemetrexed is FDA approved for 
non-squamous non-small cell lung cancer and its toxicities have been well documented 
(Cohen et al., 2010). Our study showed similar adverse events and tolerability.  
In this Phase-I clinical trial, pemetrexed was investigated as a single agent 
treatment for CNSL. The primary goal of this study was to evaluate the safety and 
tolerability of this drug. After enrolling a total of 18 patients and assessing for DLTs, the 
MTD was determined to be 900mg/m2 (dose level 2).  
Overall, pemetrexed was well tolerated but toxicities were seen and need to be 
monitored in any future studies. All patients experienced at least one type of toxicity of 
any grade. It needs to be assumed that these adverse events are at least possibly related to 
the treatment. Almost all patients (92.9%) experienced at least one neurological toxicity 
of any grade. Grade-3 toxicities included confusion, speech impairment, and psychosis. 
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Neurological SAEs included seizures of varying grades. It is unknown if these 
neurological symptoms were due to pemetrexed or due to the disease itself. Similar to 
previous clinical trials, hematological toxicities were found in this study. A majority of 
patients experienced at least one blood or bone marrow event during treatment (≥80%). 
These toxicities included anemia, thrombocytopenia, neutropenia, leukocytopenia, and 
lymphopenia. Even though most of these were grade-1 or 2, grade-3 and 4 events, as well 
as SAEs, included anemia, lymphopenia, neutropenia, and leukopenia. These toxicities 
were likely due to pemetrexed. Although it was required that patients were supplemented 
with Neupogen, folic acid and vitamin B12 to prevent these toxicities, it is possible that 
patients did not adhere to the proper treatment schedule. Metabolic toxicities were also 
common during treatment (≥80%). A majority of these were grade-1 or 2, with the 
exception of hypophosphatemia, hyperglycemia and decreased ALT, AST, creatinine. 
Constitutional and gastrointestinal symptoms were also seen in greater than 60% of 
patients. As seen in previous studies, these consisted mainly of fatigue, constipation, 
nausea, and anorexia. Musculoskeletal symptoms were also seen in greater than 60% of 
patients. The grade-3 fracture was unlikely attributable to pemetrexed, but had to be 
reported while on study. Other musculoskeletal events may have been present as baseline 
and may not have been related to drug. Less common adverse events included pain 
(<60%), infection (<40%), dermatologic, ocular/visual, and pulmonary/upper respiratory 
(<30%).  
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In addition to being well tolerated, we found evidence that pemetrexed is effective 
in treating CNSL. There were a remarkably high number of patients who had a positive 
response.  
The ORR was determined to be 92.9%. Given this data, pemetrexed is a feasible 
alternative to existing treatment options; however, certain toxicities still need to be 
closely monitored. 
This research study successfully answered the primary objectives of this phase I 
clinical trial. Some of the secondary objectives still need to be answered though and are 
under investigation. Although already collected, PK samples need to be evaluated in 
order to understand drug penetration into the CNS. These studies are currently being 
done. Additionally, we still want to examine additional tumor characteristics on the MRI 
scans performed, including MR diffusion, perfusion, and blood flow studies. 
Since this was a phase I clinical trial, the sample size was fairly small. Further 
larger studies are needed to assess the efficacy of pemetrexed in patients with CNSL. Our 
data suggests that phase II and phase III studies should be considered in larger cohorts to 
further evaluate the efficacy of this drug. Additionally, studies should be considered to 
test the effectiveness of pemetrexed in comparison to MTX treatment.   
Collectively, the present study established a MTD of 900mg/m2 in patients with 
CNS lymphoma and suggests that pemetrexed is highly effective in this disease 
population.
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APPENDICIES 
APPENDIX I: Patient Eligibility  
Inclusion Criteria (“Treatment of Recurrent Primary or Secondary Central Nervous 
System (CNS) Lymphoma With ALIMTA (Pemetrexed),” 2015) 
Patients meeting the following inclusion criteria will be eligible for the study:  
• Disease state (6 categories of patients with these extremely rare diseases are 
eligible)  
o Initial Therapy  
i. Patients with intolerance to Methotrexate – must have a diagnosis 
of B-cell non-Hodgkin’s lymphoma  
ii. Patients unable to receive methotrexate due to lack of drug 
availability – must have a diagnosis of B-cell non-Hodgkin’s 
lymphoma  
iii. Patients who fail to achieve a complete response to initial therapy 
for primary CNS lymphoma – must have a diagnosis of B-cell non-
Hodgkin’s lymphoma 
o Relapsed Disease 
iv. Recurrent Primary CNS lymphoma – If in the judgment of the 
treating physician therapy would be initiated without a repeat 
biopsy then the original biopsy with a diagnosis of B-cell non-
Hodgkin’s lymphoma will suffice  
v. Secondary CNS lymphoma - If in the judgment of the treating 
physician therapy would be initiated without a repeat biopsy then 
the original biopsy with a histologic diagnosis of B-cell non-
Hodgkin’s lymphoma will suffice  
vi. Recurrent CNS Lymphoma after prior autologous bone marrow 
transplantation for primary CNS lymphoma or primary B cell 
lymphoma 
• Definition of “diagnosis of B-cell non-Hodgkin’s Lymphoma” 
o Histologic diagnosis of B-cell non-Hodgkin’s lymphoma with measurable 
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disease OR  
o Cytologic diagnosis of B-cell non-Hodgkin’s lymphoma with measurable 
disease OR 
o Immunohistochemical diagnosis of monoclonality (CSF) with or without 
measurable intracranial disease OR 
o Molecular diagnosis of monoclonality (CSF) with or without measurable 
intracranial disease OR  
o Ocular - Patients may have a combination of histologic confirmation of 
ocular lymphoma and measurable intracranial tumor. Slit-lamp 
examination and vitreal or retinal biopsy will be done to confirm ocular 
lymphoma OR  
• Neurolymphomatosis – evidence of measurable disease as nerve seeking 
lymphoma on MRI imaging with histologic diagnosis of lymphoma at any site  
• Karnofsky score > 60 (Details on KPS scores are found in ‘Appendix II”) 
• Must be able to undergo MRI scanning Age>18Life expectancy of at least 2 
months. 
• Absolute neutrophil count > 1500/mm3, Platelets > 100,000/mm3, Creatinine 
clearance >45 ml/min and Cre <=2mg/dl. Transaminases < 3 times above the 
upper limits of the institutional norm.  
• Capable of giving informed consent or having a designated medical proxy signing 
for them.  
• Must be willing to practice an effective method of birth control during 
participation in the study, whether male or female. 
• Patients with prior autologous bone marrow transplantation are eligible for this 
study.  
Exclusion Criteria (“Treatment of Recurrent Primary or Secondary Central Nervous 
System (CNS) Lymphoma With ALIMTA (Pemetrexed),” 2015)  
Patients with the following conditions will be excluded from participation in the study:  
• Definitive histologic diagnosis of low-grade lymphoma without substantive 
clinical suspicion of transformation to an aggressive lymphoma 
• Renal dysfunction defined as creatinine clearance < 45 ml/min or serum 
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creatinine > 2mg/dL 
• Transaminases > 3 times above the upper limits of the institutional norm 
• Acute infection, granulocytopenia or medical condition precluding surgery as 
judged by the caring physician and review team 
• Pregnant or lactating females 
• Patients must not have pre-existing immunosuppression, concurrent 
immunosuppressive treatment (with the exception of dexamethasone) 
• Patients must not have received prior whole brain irradiation. They can have 
received prior focal brain irradiation. 
• Prior participation in chemotherapy, cytotoxic therapy, immunotherapy or 
therapeutic protocols within 2 weeks of enrollment. Patients unable to stop 
NSAIDS or Cox-2 inhibitors for two days before and after treatment as well as the 
day of treatment. 
• No other active systemic malignancy with the exception of basal cell carcinoma 
of the skin and cervical carcinoma in situ. Patients with a remote history (≥ 5 
years) of malignancy are eligible for the protocol in the absence of active disease. 
• Clinically relevant third space fluid collection refractory to drainage 
• Patient refusal to participate in the PK study  
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APPENDIX II: The Karnofsky Performance Status (KPS) Determination Scale  
 
100  Normal, no complaints, no evidence of disease
90  Able to carry on normal activity; some minor symptoms  
80  Normal activity with some effort; some symptoms
70  Care for self; unable to carry on normal activities
60  Requires occasional assistance; cares for most needs
50  Requires considerable assistance and frequent care
40  Disabled; requires special care and assistance
30  Severely disabled; hospitalized, death not imminent
20  Very sick; active support treatment needed
10  Moribund; fatal processes are rapidly progressing 
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APPENDIX III: Study Schedule 
Table 8. Patent Study Schedule for Cycles 1 and 2 
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Table 9. Patient Study Schedule for Cycles Beyond Cycle 2 
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APPENDIX IV: DFHCC Standard Operating Procedures for Human Subject 
Research (Version 5, 2/8/14) (“Adverse Events,” 2014) 
TITLE: Reporting Adverse Events 
SOP #: RCO-204 (formerly AE-601) 
Effective Date: 3/1/14 
1. POLICY STATEMENT: The research team is responsible for recognizing 
changes in subject health that may qualify as adverse events, classifying those 
results as defined in the relevant regulations and reporting those events to the 
sponsor, the applicable Institutional Review Board (IRB) and, when required, to 
the appropriate regulatory authorities.  
2. BACKGROUND: The research team is responsible for protecting the safety, 
rights and well-being of subjects. The recording and reporting of adverse events 
which occur during the course of the research ensure the continuing safety of 
subjects.  
3. RESPONSIBLE PERSONNEL: 
3.1.Overall Principal Investigator (PI) 
3.2.Site Responsible Investigator 
3.3.Subinvestigator 
3.4.Research Nurse 
3.5.Study Coordinator 
4. DEFINITIONS: 
4.1. Adverse Event (AE) (FDA definition): An untoward medical occurrence 
associated with the use of a drug in humans, whether or not considered drug 
related. An AE can be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a drug, without any judgment about causality.  
4.2. Attribution: The determination of whether there is a causal relationship between 
an adverse event and the investigational product or intervention.  
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4.3. Life-threatening Adverse Event: An adverse event that places the subject, in the 
view of either the investigator or sponsor, at immediate risk of death. It does not 
include a reaction that had it occurred in a more severe form, might have caused 
death.  
4.4. Serious Adverse Event (SAE) or Serious Suspected Adverse Reaction (FDA 
definition): An adverse event occurring at any dose that, in the view of either the 
investigator or sponsor, results in any of the following outcomes: death, a life-
threatening adverse event, inpatient hospitalization or prolongation of existing 
hospitalization (for > 24 hours), a persistent or significant incapacity or 
substantial disruption of the ability to conduct normal life functions, or a 
congenital anomaly/birth defect. Important medical events that may not result in 
death, be life-threatening or require hospitalization may be considered serious 
when, based upon appropriate medical judgment, they may jeopardize the subject 
and may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition.  
4.5. Suspected Adverse Reaction (FDA definition): An adverse drug event for which 
there is a reasonable possibility that the drug caused the adverse event. For the 
purposes of safety reporting, “reasonable possibility” means there is evidence to 
suggest a causal relationship between the drug and the adverse event.  
4.6.Unanticipated Adverse Device Event (UADE): Any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated 
with, a device, if that effect, problem, or death was not previously identified in 
nature, severity, or degree of incidence in the investigational plan or application 
(including a supplementary plan or application), or any other unanticipated 
serious problem associated with a device that relates to the rights, safety, or 
welfare of subjects.  
4.7. Unexpected Adverse Event or Unexpected Suspected Adverse Reaction (FDA 
definition): An adverse event that is not listed in the investigator brochure or is 
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not listed at the specificity or severity that has been observed; or, if an 
investigator brochure is not required or available, is not consistent with the risk 
information described in the general investigational plan or elsewhere in the 
current protocol. “Unexpected” as used in this definition, also refers to an adverse 
event or suspected adverse reaction that has not been previously observed (e.g., 
included in the investigator brochure) rather than from the perspective of such 
experience not being anticipated from the pharmacological properties of the drug. 
4.8. Unexpected Adverse Event (NCI definition): Any adverse event which is not 
listed in the National Cancer Institute (NCI) Agent Specific Expected Adverse 
Event List. 
5. PROCEDURE: 
5.1. The Overall PI and all applicable research team members will review the 
investigator’s brochure and any safety reports released by the Sponsor at the start 
of the research and for the duration of the research to become familiar with the 
safety profile of the investigational drug/device or intervention. 
5.2. The Overall PI and all applicable research team members will review the 
protocol, informed consent document and the IRB’s standard operating 
procedures to be familiar with the Sponsor’s and the IRB’s requirements for 
reporting site-specific serious adverse events.  
5.3. During the course of the research, the Overall PI and all applicable research 
fteam members will identify any information that may indicate that an adverse 
event may have occurred. This information may come from several different 
sources and persistent discussions with the subject may be required to learn of 
these events. Possible sources of adverse event information include:  
5.3.1. Information obtained during a scheduled clinic or research visit 
5.3.2. Emergency room or other hospital records – including hospital visits which 
may have occurred in other cities or states 
5.3.3. Laboratory reports indicating significant harmful changes 
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5.3.4. Changes in medication that the subject may be taking 
5.3.5. Visits to new physicians the subject did not previously consult 
5.3.6. Any other medically significant information or records that indicate that a 
negative change from baseline may have occurred.  
5.4. Once an adverse event has been identified, the elements of adverse assessment 
(grade of severity, attribution, and duration of event) and any 
treatment/medication received specifically related to the event are recorded in the 
subject’s medical record or research chart (as applicable). This must be done in a 
reasonable amount of time. 
5.5. If an adverse event is not related to the investigational drug/device or 
intervention, then documentation of expectedness is not required. 
5.6. Attribution (i.e. the causal relationship to the investigational drug/device or 
intervention) must be determined by the Overall PI or a medically-qualified 
research team member.  
5.6.1. If an initial determination of attribution is recorded by a research nurse or 
study coordinator, there must be clear documentation that the Overall PI or 
another protocol physician reviewed the adverse event information and agrees 
with the initial determination. Co-signatures without a statement of 
affirmation are not acceptable.  
5.7. Serious adverse events or serious suspected adverse reactions will be discussed 
with the Overall PI prior to submission to the Sponsor or IRB. In the event that 
timely reporting does not permit this discussion, the Overall PI must be informed 
of serious adverse events at the time of submission to the Sponsor and IRB. 
5.8. Adverse events occurring during the course of the research are reported to the 
Sponsor following the sponsor’s requirements.  
5.9. All adverse events are followed until resolution or for the duration specified in 
the protocol by the Overall PI or a medically-qualified member of the research 
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team. All relevant follow-up information, i.e. treatment and findings, are recorded 
in the subject’s medical record.  
5.10. All adverse events occurring during the course of the research are reported 
to the IRB following the IRB’s requirements. 
5.11. Additional reporting requirements may apply for investigator-held 
Investigational New Drug (IND) application or Investigational Device 
Exemptions (IDE) research, secondary malignancies or gene therapy research. 
Adverse events for these types of research are reported to the Food and Drug 
Administration (FDA) and/or other appropriate regulatory authorities following 
the reporting requirements set by the respective regulatory authority. 
5.12. For IND Safety Reports received from the Sponsor, the Overall PI will 
follow the IRB’s policy on Receipt and Review of IND/IDE Safety Reports to 
determine which events from other sites must be reported to the IRB and 
discussed with the research team.  
6. APPLICABLE REGULATIONS & GUIDELINES:  
21 CFR 50 – Protection of Human Research Subjects 
21 CFR 54 – Financial Disclosure by Clinical Investigators 
21 CFR 56 – Institutional Review Boards 
21 CFR 312 - Investigational New Drugs – Drugs for Human Use  
21 CFR 812 – Investigational New Device Exemptions 
45 CFR 46 – Human Subject Protections 
FDA Industry Guidelines and Information Sheets 
FDA Compliance Policy Guidance Programs: 7348.809, 7348.810, and 7348.811 
7. RELATED REFERENCES:  
International Conference on Harmonisation – E6 
OHRS Information Sheet: DFCI IRB Adverse Event Reporting Policy 
OHRS Information Sheet: Policy on Receipt and Review of IND/IDE Safety 
Reports 
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8. RELATED FORMS & TOOLS:  
DFCI IRB Serious Adverse Event Reporting Form  
NCI Common Toxicity Criteria for Adverse Events (CTCAE) 
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APPENDIX V: Patient Summary 
Table 10. Subject Data Summary 
Subject 
ID Age Gender Disease State 
Dose Level  
(mg/m2) 
Length 
on Tx 
Response 
(CR, PR, 
SD, PD) 
CR at 
cycle 
1 76 F Recurrent PCNSL 600 2 PR  
2 77 M Recurrent PCNSL 600 5 PR   
3 66 M Recurrent PCNSL 600 10 PR   
4 68 F Recurrent PCNSL 600 4 SD   
5 79 F Recurrent PCNSL 600 N/A N/A   
6 64 M Initial PCNSL, intolerant of MTX 600 7 PR   
7 53 F Recurrent PCNSL 600 2 PD   
8 71 M Recurrent SCNSL 900 5 SD   
9 67 M Initial PCNSL, intolerant of MTX 900 4 SD   
10 54 F Recurrent PCNSL 900 10 CR 9 
11 49 M Recurrent PCNSL 1200 1 N/A   
12 72 F Recurrent PCNSL 1200 10 SD   
13 66 F Recurrent PCNSL 1200 12 CR 9 
14 51 M Recurrent PCNSL 1200 6 PR   
15 61 M Recurrent SCNSL 1200 1 N/A   
16 47 M Recurrent PCNSL 1200 10 CR 3 
17 68 F Recurrent PCNSL 900 1 N/A   
18 73 F Recurrent PCNSL 1200 3 CR 3 
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Developed and conducted a household survey in rural Tanzania, analyzed data, wrote a 
final report, and reported findings back to community and key stakeholders. 
Sargent Internship/Practicum: Massachusetts General Hospital 01/2011 – 05/2011 
OR Department, Clinical Intern 
Implementation of improvement safety strategies for surgeries, pathology and specimen 
submission, room turnover and patient care research 
Physician Shadowing 
Massachusetts General Hospital - W. Curry; M. Flaherty 2011; 2015 
Summit Medical Group, NJ – J. Siegal   05/2009 – 09/2010 
Children’s Hospital Boston – Developmental Medicine, Boston, MA 08/2012 – 2014 
Observing patient appointments including developmental tests in cooperation with a 
social worker and neuropsychiatrist, Dr. Peter Schuntermann; Participation in the analysis 
and discussion of patients with the developmental team. Speaker at monthly therapy 
group of adolescents with autistic siblings. 
Lurie Center for Autism (/LADDERS/MGH) – Lexington, MA 08/2012 - 2014 
Dr. Timothy Yu, Neurologist, Post-doctoral fellow Children’s Genetics 
Directly observing his appointments with autistic and neurologically and/or genetically 
affected children.    
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